After the Federal Reserve made its second consecutive quarter-point cut this past week, Chair Jerome Powell said “there were ...
EagleOne Metals Corporation (CSE: EAGL) ("EagleOne" or the "Company") is pleased to report the results of its Phase 1 exploration program on the Magusi West Gold Project it holds in southern Hebecourt ...
Gold and silver’s recent price pullbacks reflect transient profit-taking rather than a reversal of trend. Click here to read ...
Opinion
8hon MSNOpinion
US squeeze on Venezuela won’t bring about rapid collapse of Maduro – in fact, it might boomerang on Washington
Nicolás Maduro, the country’s leader since 2013, is taking no chances. In recent weeks he responded to the Trump administration’s moves as if invasion were imminent. After a September emergency decree ...
In the latest policy decision, the FOMC lowered the policy rate by 25 basis points on expected lines, bringing the federal funds rate to the 3.75 per cent-4.00 per cent range. Alongside the rate cut, ...
6don MSN
CPI report shows inflation continued to climb in September, although at a cooler pace than forecast
Inflation last month rose at an annual rate of 3%, coming in below economists' forecasts as the impact of President Trump's ...
The Federal Reserve’s string of interest rate cuts could come to an end at its last meeting of the year in December after it ...
Howard Marks explains how risk tolerance shapes investment decisions and board behavior. Learn how to align strategy with ...
The National Interest on MSN
The Pentagon Doesn’t Like the New Film “A House of Dynamite”
DoD officials criticized the new Kathryn Bigelow film for depicting efforts to intercept a nuclear missile as a “coin toss,” stressing higher reliability rates.
From the sprawling urban centers to emerging satellite towns, AI is ushering in an era of unprecedented efficiency, ...
More than 100 memorials at a village graveyard have been identified as “unstable and potentially hazardous” following an ...
During BMS’ earnings call Thursday, CEO Chris Boerner, Ph.D., described Cobenfy as “delivering steady growth.” But the first-in-class drug still has a long way to go to fulfill its promise as a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results